In Vivo Screening of Radioprotectors.
Annual summary rept. Sep 80-Aug 81,
LITTLE (ARTHUR D) INC CAMBRIDGE MA
Pagination or Media Count:
The purpose of this work is to establish an in vivo screening capability for the USAMRDC and to begin evaluating the ability of submitted compounds to protect normal body tissues from radiation injury. Experimental animals were chosen on the basis of general health, freedom from specific pathogens, radiation response, and supplier capability. Three mouse strains were considered and mice from five suppliers were evaluated. Female C57B16 mice from the Charles River Breeding Laboratories were chosen. Radiation doses which cause death to 50 and 99 of mice from bone-marrow radiation injury were 809 rads and 971 rads, respectively. Twenty-five compounds were received for radioprotectant evaluation. Eight of these agents, known radioprotectors, underwent detailed drug toxicity testing prior to being entered into radioprotector testing protocols. Drug toxicity data were also used to establish maximally tolerated nontoxic doses to be used in radioprotector studies. Seventeen newly synthetized compounds are currently being evaluated as antiradiation drugs.